Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Oxandrolone and Raloxifene Interaction: Avoid | Peptide Database

Compound Profiles Oxandrolone Oral Anabolic Steroid | Lean Mass & Recovery Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tiss

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Oxandrolone

Oral Anabolic Steroid | Lean Mass & Recovery

Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia.

Raloxifene

Selective Estrogen Receptor Modulator | Gynecomastia & Bone Health

Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Oxandrolone with Raloxifene?

Combining Oxandrolone with Raloxifene is not recommended. Both Oxandrolone and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Oxandrolone and Raloxifene safe together?

This combination carries significant risk. Both Oxandrolone and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Oxandrolone and Raloxifene?

Both Oxandrolone and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Oxandrolone and Raloxifene?

Oxandrolone has a half-life of ~9-10 hours and Raloxifene has a half-life of ~28 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching BAM-15 — share findings, ask questions, and learn from real experiences BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products. BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.

Source: peptide-db.com ↗

Community Research

Join others researching Vesugen — share findings, ask questions, and learn from real experiences Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression. Vesugen works through epigenetic regulation by interacting with DNA promoter regions, particularly affecting Ki-67 gene expression which controls cell division. It plays a prominent role in regulating sirtuin 1 (SIRT1) protein levels - a key anti-aging protein activated during calorie restriction. Vesugen enhances mesenchymal stem cell proliferation, reduces senescence markers, improves cell differentiation, and may reverse the Senescence-Associated Secretory Phenotype (SASP) implicated in age-related cardiovascular disease.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to Stack Them

A practical approach based on evidence tiers: Foundation (everyone): CoQ10 100-300mg daily (especially if on statins or over 50) Creatine 3-5g daily Second layer (longevity-focused): NMN 250-500mg or NR 300mg daily Urolithin A 500-1000mg daily Research tier (advanced, with medical oversight): NAD+ IV 250-500mg weekly or SubQ 100-500mg 2-3x weekly SS-31 5-10mg daily SubQ MOTS-c 5-10mg daily SubQ (WADA prohibited) Check interactions between any peptides in your stack: Interaction checker Use our cost calculator to work out per-dose pricing.

Source: peptide-db.com ↗
Dosage reference

Dosing Protocols

Available in capsule form for oral administration. As a tripeptide, Chonluten has favorable permeability across cellular compartments. Typical protocol involves 10-20 day cycles. Standard protocol 10-20 mg Daily for 10-20 days Oral capsules Maintenance 10 mg 2-3 cycles yearly

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →